Savara Inc (NASDAQ:SVRA) Shares Bought by Northern Trust Corp

Northern Trust Corp increased its stake in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 9.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,077,363 shares of the company's stock after purchasing an additional 89,573 shares during the quarter. Northern Trust Corp owned 0.63% of Savara worth $3,308,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of SVRA. Susquehanna Fundamental Investments LLC acquired a new position in shares of Savara during the fourth quarter worth about $702,000. Price T Rowe Associates Inc. MD grew its holdings in Savara by 13.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock worth $135,000 after acquiring an additional 5,236 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Savara in the 4th quarter valued at approximately $48,000. Dimensional Fund Advisors LP increased its position in shares of Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock valued at $441,000 after purchasing an additional 5,450 shares during the last quarter. Finally, Altium Capital Management LLC lifted its position in shares of Savara by 0.3% during the 4th quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock worth $4,848,000 after purchasing an additional 4,000 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Price Performance

Savara stock traded up $0.11 during mid-day trading on Thursday, reaching $2.24. The company had a trading volume of 2,519,272 shares, compared to its average volume of 1,421,727. Savara Inc has a 1 year low of $1.89 and a 1 year high of $5.11. The company has a market capitalization of $387.15 million, a P/E ratio of -5.21 and a beta of 0.44. The stock's 50-day simple moving average is $2.93 and its 200-day simple moving average is $2.96. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). On average, equities analysts predict that Savara Inc will post -0.45 EPS for the current year.

Analysts Set New Price Targets

SVRA has been the subject of several research analyst reports. HC Wainwright cut shares of Savara from a "buy" rating to a "neutral" rating and lowered their target price for the company from $6.00 to $2.00 in a report on Thursday. Wells Fargo & Company reduced their target price on Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday. Evercore ISI dropped their price target on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research note on Wednesday. Finally, Guggenheim reiterated a "buy" rating and issued a $8.00 price objective (down previously from $9.00) on shares of Savara in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $7.17.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.